SMYD3 is altered in 1.09% of all cancers with endometrial endometrioid adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, cutaneous melanoma, and invasive breast carcinoma having the greatest prevalence of alterations .
The most common alterations in SMYD3 are SMYD3 Amplification (0.43%), SMYD3 Loss (0.04%), SMYD3 S154L (0.02%), SMYD3 A252V (0.01%), and SMYD3 R165* (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.